
MK-4827
CAS No. 1038915-60-4
MK-4827( Niraparib | MK 4827 | MK4827 )
Catalog No. M10194 CAS No. 1038915-60-4
MK-4827 (Niraparib, MK4827) is a highly potent PARP inhibitor with IC50 of 3.8 nM/2.1 nM for PARP1/PARP2.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 50 | In Stock |
![]() ![]() |
10MG | 72 | In Stock |
![]() ![]() |
25MG | 107 | In Stock |
![]() ![]() |
50MG | 132 | In Stock |
![]() ![]() |
100MG | 205 | In Stock |
![]() ![]() |
500MG | 516 | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameMK-4827
-
NoteResearch use only, not for human use.
-
Brief DescriptionMK-4827 (Niraparib, MK4827) is a highly potent PARP inhibitor with IC50 of 3.8 nM/2.1 nM for PARP1/PARP2.
-
DescriptionMK-4827 (Niraparib, MK4827) is a highly potent PARP inhibitor with IC50 of 3.8 nM/2.1 nM for PARP1/PARP2; inhibits PARP activity with EC50=4 nM in a whole cell assay, and inhibits proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC50 in the 10?100 nM range; well tolerated in vivo and demonstrates efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer.Ovarian Cancer Approved(In Vitro):Niraparib (MK-4827) inhibits PARP activity with EC50=4 nM and EC90=45 nM in a whole cell assay. MK-4827 inhibits proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC50 in the 10-100 nM range. MK-4827 displays excellent PARP 1 and 2 inhibition with IC50=3.8 and 2.1 nM, respectively, and in a whole cell assay. To validate that Niraparib (MK-4827) inhibits PARP in these cell lines, A549 and H1299 cells are treated with 1 μM MK-4827 for various times and measured PARP enzymatic activity using a chemiluminescent assay. The results show that Niraparib (MK-4827) inhibits PARP within 15 minutes of treatment reaching about 85% inhibition in the A549 cells at 1 h and about 55% inhibition at 1 h for the H1299 cells.(In Vivo):Niraparib (MK-4827) is well tolerated and demonstrates efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer. Niraparib (MK-4827) is well tolerated in vivo and demonstrates efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer. Niraparib (MK-4827) is characterized by acceptable pharmacokinetics in rats with plasma clearance of 28 (mL/min)/kg, very high volume of distribution (Vdss=6.9 L/kg), long terminal half-life (t1/2=3.4 h), and excellent bioavailability, F=65%. Niraparib (MK-4827) enhances radiation response of p53 mutant Calu-6 tumor in both cases, with the single daily dose of 50 mg/kg being more effective than 25 mg/kg given twice daily.
-
In VitroNiraparib (MK-4827) inhibits PARP activity with EC50=4 nM and EC90=45 nM in a whole cell assay. MK-4827 inhibits proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC50 in the 10-100 nM range. MK-4827 displays excellent PARP 1 and 2 inhibition with IC50=3.8 and 2.1 nM, respectively, and in a whole cell assay. To validate that Niraparib (MK-4827) inhibits PARP in these cell lines, A549 and H1299 cells are treated with 1 μM MK-4827 for various times and measured PARP enzymatic activity using a chemiluminescent assay. The results show that Niraparib (MK-4827) inhibits PARP within 15 minutes of treatment reaching about 85% inhibition in the A549 cells at 1 h and about 55% inhibition at 1 h for the H1299 cells.
-
In VivoNiraparib (MK-4827) is well tolerated and demonstrates efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer. Niraparib (MK-4827) is well tolerated in vivo and demonstrates efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer. Niraparib (MK-4827) is characterized by acceptable pharmacokinetics in rats with plasma clearance of 28 (mL/min)/kg, very high volume of distribution (Vdss=6.9 L/kg), long terminal half-life (t1/2=3.4 h), and excellent bioavailability, F=65%. Niraparib (MK-4827) enhances radiation response of p53 mutant Calu-6 tumor in both cases, with the single daily dose of 50 mg/kg being more effective than 25 mg/kg given twice daily. Animal Model:Female nude mice (Ncr Nu/Nu) with solitary tumor xenografts Dosage:25 mg/kg or 50 mg/kg Administration:Gavage, 25 mg/kg twice a day with 6 h between doses or 50 mg/kg once daily for 21 consecutive days Result:Enhanced radiation response.
-
SynonymsNiraparib | MK 4827 | MK4827
-
PathwayCell Cycle/DNA Damage
-
TargetPARP
-
RecptorPARP1|PARP2|PARP3|TANK-1|V-PARP
-
Research AreaCancer
-
IndicationOvarian Cancer
Chemical Information
-
CAS Number1038915-60-4
-
Formula Weight320.3883
-
Molecular FormulaC19H20N4O
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 32 mg/mL
-
SMILESC1C[C@H](CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N
-
Chemical Name2H-Indazole-7-carboxamide, 2-[4-(3S)-3-piperidinylphenyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Jones P, et al. J Med Chem. 2009 Nov 26;52(22):7170-85.
2. Bridges KA, et al. Oncotarget. 2014 Jul 15;5(13):5076-86.
3. Mirza MR, et al. N Engl J Med. 2016 Dec 1;375(22):2154-2164.
molnova catalog



related products
-
Amelparib hydrochlor...
Amelparib hydrochloric hydrate (JPI-289, JPI289) is a novel potent, water soluble PARP-1 inhibitor with IC50 of 18.5 nM, inhibits cellular PAR formation with IC50 of 10.7 nM.
-
MK-4827 hydrochlorid...
A highly potent PARP inhibitor with IC50 of 3.8 nM/2.1 nM for PARP1/PARP2.
-
Gemcabene calcium
Gemcabene (PD-72953, PD72953) is a first-in-class lipid-lowering agent and activator of PARP.